Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
CRISPR Therapeutics (Nasdaq: CRSP) announced promising preclinical data from its allogeneic CAR-T program at the AACR Annual Meeting 2021. The study showcased that CAR-T cells with CD70 knockout displayed enhanced potency and persistence compared to conventional CAR-T cells. The research explored the effects of CRISPR/Cas9 gene editing on various checkpoint genes, revealing CD70's superior efficacy. The ongoing clinical trials of CTX130, targeting CD70-expressing tumors, expect to report top-line data in 2021, marking a significant step in cancer treatment innovation.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 a.m. ET. Members of the senior management team will represent the company.
A live webcast will be available on the company's Investors page, with a replay archived for 14 days following the event. CRISPR Therapeutics is focused on developing gene-based medicines using its proprietary CRISPR/Cas9 platform, targeting serious diseases across various fields.
CRISPR Therapeutics (Nasdaq: CRSP) will present a poster at the AACR Annual Meeting, focusing on a novel approach to augment CAR-T cell function through CD70 knockout technology. The presentation is scheduled for April 10, 2021, at 8:30 a.m. ET. This virtual event will showcase advancements in immunology and the potential of CRISPR's gene-editing platform. The company aims to develop transformative medicines for serious diseases, leveraging collaborations with industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) announces its participation in two upcoming virtual investor conferences in March 2021. The Barclays Global Healthcare Conference will take place on March 9, 2021, at 10:20 a.m. ET, and the 33rd Annual Roth Conference is scheduled for March 15, 2021, at 1:30 p.m. ET. Investors can access live webcasts through the company's website, with replay available for 14 days post-event. CRISPR Therapeutics is a leader in gene editing, developing transformative medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
CRISPR Therapeutics (Nasdaq: CRSP) reported its fourth quarter and full-year 2020 financial results, highlighting a net loss of $107 million for Q4 and $348.9 million for the year. Collaboration revenue dramatically decreased to $0.2 million in Q4 2020 from $77 million in Q4 2019. Research and development expenses increased to $82.4 million in Q4 2020 due to advancements in its clinical programs. More than 20 patients have been dosed in the ongoing trials of CTX001 for certain blood disorders, with expected completion in 2021, marking a pivotal year for growth.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 12, 2021, at 3:30 p.m. ET. Senior management team members will represent the company during this event. A live webcast is available on the company's Investors website, with a replay accessible for 14 days post-event. CRISPR Therapeutics focuses on developing transformative gene-based medicines utilizing its proprietary CRISPR/Cas9 technology, with initiatives across various disease areas such as oncology and hemoglobinopathies.
CRISPR Therapeutics (Nasdaq: CRSP) appointed Philippe Drouet as Chief Commercial Officer on February 1, 2021. Drouet, with over 20 years in global pharmaceutical marketing, is expected to drive the company’s commercialization efforts. His previous roles include Senior VP at Merck, where he led the launch of Keytruda, and President of Hospira’s U.S. division. The CEO emphasized Drouet's leadership will be crucial as CRISPR advances its gene-based therapies across oncology and hematology.
CRISPR Therapeutics (CRSP) announced a grant from the Bill & Melinda Gates Foundation to support research on CRISPR/Cas9-based therapies for HIV. The funding aims to enhance in vivo gene editing capabilities, allowing broader access to transformative treatments, particularly in resource-limited settings. This grant builds upon CRISPR's expertise in editing hematopoietic stem cells and aligns with its commitment to global health.
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals reported promising data for CTX001, a CRISPR/Cas9 gene-editing therapy, at the ASH Meeting. In beta thalassemia, all seven patients were transfusion independent after 3 to 18 months post-infusion. For sickle cell disease, three patients experienced no vaso-occlusive crises within 3 to 15 months. The New England Journal of Medicine published a peer-reviewed article detailing these findings. CTX001 is being advanced through Phase 1/2 trials and has received several FDA designations to expedite its development.
CRISPR Therapeutics and Vertex Pharmaceuticals will host an investor webcast on December 9, 2020, at 8:00 a.m. ET. The event will focus on clinical data from ongoing Phase 1/2 trials of CTX001, a gene-editing therapy for sickle cell disease and beta thalassemia, which will be presented at the ASH Meeting. Notable speakers include representatives from both companies and Dr. Haydar Frangoul. The webcast will be accessible via the companies' websites, and an archived version will be available for 30 days.
The collaboration aims to develop gene-based treatments using CRISPR/Cas9 technology.